drugset

drugset / Trial / NCT04748601

Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old

NCT04748601 ↗

Phase 4 Recruiting 132 enrolled Upsher-Smith Laboratories

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Phase 4 study to evaluate Qudexy XR for the prevention of migraine in children 6 to 11 years of age.

Timeline

Start: 2021-02-19
Primary completion: 2026-09
Completion: 2026-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Topiramate	Small molecule	—	—

Indications